Heterogeneity of susceptibility to fluoroquinolones in Bartonella isolates from Australia reveals a natural mutation in gyrA

Journal of Antimicrobial Chemotherapy

Volumn 61, Issue 6, 2008, Pages 1252-1255

  Angelakis, Emmanouil ^a   Biswas, Silpak ^a   Taylor, Carmel ^b   Raoult, Didier ^a   Rolain, Jean Marc ^a  

^a CNRS   (France)

^b Public Health Virology   (Australia)

Author keywords

DNA gyrase; Etest diffusion assay; Resistance

Indexed keywords

AMOXICILLIN; AZITHROMYCIN; BETA LACTAM; BETA LACTAM ANTIBIOTIC; CEFTRIAXONE; CIPROFLOXACIN; CLARITHROMYCIN; DNA TOPOISOMERASE (ATP HYDROLYSING) A; ERYTHROMYCIN; IMIPENEM; MACROLIDE; OFLOXACIN; PRIMER DNA; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TETRACYCLINE; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; AUSTRALIA; BACTERIAL MUTATION; BACTERIUM ISOLATE; BARTONELLA; BARTONELLA BACILLIFORMIS; BARTONELLA HENSELAE; BARTONELLA QUINTANA; DNA SEQUENCE; EPSILOMETER TEST; GENETIC HETEROGENEITY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; POLYMERASE CHAIN REACTION;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANIMALS; ANIMALS, WILD; ANTI-BACTERIAL AGENTS; AUSTRALIA; BARTONELLA BACILLIFORMIS; BARTONELLA HENSELAE; BARTONELLA INFECTIONS; BARTONELLA QUINTANA; DNA GYRASE; DNA, BACTERIAL; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; MICROBIAL SENSITIVITY TESTS; MOLECULAR SEQUENCE DATA; POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS, DNA;

EID: 44449092513     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkn094     Document Type: Article

References (10)

1. Birtles RJ, Raoult D. Comparison of partial citrate synthase gene ( gltA) sequences for phylogenetic analysis of Bartonella species. Int J Syst Bact 1996; 46: 891-7.
2. Rolain jM, Brouqui P, Koehler JE et al. Recommendations for treatment of human infections caused by Bartonella species. Antimicrob Agents Chemother 2004; 48: 1921-33.
3. Meghari S, Rolain JM, Grau GE et al. Anti-angiogenic effect of erythromycin in Bartonella quintana: In vitro model of infection. J Infect Dis 2006; 193: 380-6.
4. Biswas S, Raoult D, Rolain JM. Molecular mechanisms of resistance to antibiotics in Bartonella bacilliformis. J Antimicrob Chemother 2007; 59: 1065-70.
5. Pendle S, Ginn A, Iredell J. Antimicrobial susceptibility of Bartonella henselae using Etest methodology. J Antimicrob Chemother 2006; 57: 761-3.
6. Ives TJ, Marston EL, Regnery RL et al. In vitro susceptibilities of Bartonella and Rickettsia spp. to fluoroquinolone antibiotics as determined by immunoflourescent antibody analysis of infected Vero cell monolayers. Int J Antimicrob Agents 2001; 18 217-22.
7. Kordick DL, Papich MG, Breitschwerdt B. Efficacy of enrofloxacin or doxycycline for treatment of Bartonella henselae or Bartonella clarridgeiae infection in cats. Antimicrob Agents Chemother 1997; 41: 2448-55.
8. Heisig P, Tschorny R. Characterization of fluoroquinolone-resistant mutants of Escherichia coli selected in vitro. Antimicrob Agents Chemotner 1994; 38: 1284-91.
9. Minnick MF, Wilson ZR, Smitherman LS et al. gyrA mutations in ciprofloxacin-resistant Bartonella bacilliformis strains obtained in vitro. Antimicrob Agents Chemother 2003; 47: 383-6.
10. Masselot F, Boulos A, Maurin M et al. Molecular evaluation of antibiotic susceptibility, the Tropheryma whipplei paradigm. Antimicrob Agents Chemother 2003; 47: 1658-64.